Cardiology and cardiovascular disease Archives - Page 6 of 13

New and emerging lipid-modifying drugs to lower LDL cholesterol

Constantine E Kosmas, Dafni Pantou, Andreas Sourlas, Evangelia J Papakonstantinou, Rogers Echavarria Uceta, Eliscer Guzman

Article Type

Review

Published

01 Nov 2021

This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying low-density lipoprotein-cholesterol-lowering drugs.

Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm

Xavier Garcia-Moll, Vivencio Barrios, Josep Franch-Nadal

Article Type

Commentary

Published

18 Aug 2021

This article discusses how patients with diabetes should be treated
according to their CV risk considered as a continuum and not simply as falling within primary or secondary prevention.

Advances in safe insulin infusions

Fred Massoomi, Maureen Burger, Christine de Vries

Article Type

Review

Published

15 Jul 2021

This narrative review explores the expanding indications, risks and opportunities associated with insulin infusions and potential options for improved safety.

Ertugliflozin in the treatment of type 2 diabetes mellitus

Joel C Marrs PharmD, MPH, Sarah L Anderson PharmD

Article Type

Review

Published

30 Nov 2020

This narrative review aims to present and discuss the efficacy, safety, cardiovascular, and renal outcomes related to the use of ertugliflozin in Type 2 diabetes.

Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease

Namrata Singhania MD, Saurabh Bansal MD, Shreya Mohandas, Divya P Nimmatoori MD, Abutaleb A Ejaz MD, Girish Singhania MD

Article Type

Review

Published

11 Nov 2020

This narrative review summarizes the role of renin–angiotensin–aldosterone system inhibitors in acute and chronic heart failure and chronic kidney disease.